BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed NVO catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:4efa60f6e64c2d5af55a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:NVO P2 readout (est.): A Research Study on How Well Different Doses
  of the Medicine NNC0662-0419 Help People Living With Overweight or Obesit
 y
DESCRIPTION:A Research Study on How Well Different Doses of the Medicine NN
 C0662-0419 Help People Living With Overweight or Obesity\nNCT07184632 | PH
 ASE2 | ACTIVE_NOT_RECRUITING | sponsor: Novo Nordisk A/S\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nTicker NVO (
 confidence 0.95)\nSource: https://clinicaltrials.gov/study/NCT07184632\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07184632
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:36f917ed2eab1e1ca680@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:NVO P2 readout (est.): A Research Study on How Well Different Doses
  of the Medicine UBT251 Help People Living With Overweight or Obesity
DESCRIPTION:A Research Study on How Well Different Doses of the Medicine UB
 T251 Help People Living With Overweight or Obesity\nNCT07395687 | PHASE2 |
  RECRUITING | sponsor: Novo Nordisk A/S\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nTicker NVO (confidence 0.95)\
 nSource: https://clinicaltrials.gov/study/NCT07395687\nScheduling/referenc
 e data from public records\; dates can move. Not investment\, legal or med
 ical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07395687
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6c041788a2636017be7e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:NVO P3 readout (est.): ONWARDS 11
DESCRIPTION:A Research Study to See How a Weekly Insulin\, Insulin Icodec\,
  Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine\, Bo
 th in Combination With Insulin Aspart\, in Adults With Type 1 Diabetes\nNC
 T07076199 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Novo Nordisk A/S\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nTicker NVO (confidence 0.95)\nSource: https://clinicaltrials.gov/study/N
 CT07076199\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07076199
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:01816cc47c910dc989c5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:NVO P3 readout (est.): ARTEMIS
DESCRIPTION:ARTEMIS - A Research Study to Look at How Ziltivekimab Works Co
 mpared to Placebo in People With a Heart Attack\nNCT06118281 | PHASE3 | AC
 TIVE_NOT_RECRUITING | sponsor: Novo Nordisk A/S\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nTicker NVO (confidenc
 e 0.95)\nSource: https://clinicaltrials.gov/study/NCT06118281\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06118281
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ea40eba7fb9c4ce3c927@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261024
SUMMARY:NVO APPROVAL: AWIQLI FLEXTOUCH
DESCRIPTION:Approved 2026-10-23: AWIQLI FLEXTOUCH (BLA761326 SUPPL1)\nConfi
 dence: confirmed\nTicker NVO (confidence 0.95)\nSource: https://www.access
 data.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=7613
 26\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761326
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2f6140475797226791b4@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260326
DTEND;VALUE=DATE:20260327
SUMMARY:NVO APPROVAL: AWIQLI FLEXTOUCH
DESCRIPTION:Approved 2026-03-26: AWIQLI FLEXTOUCH (BLA761326 ORIG2)\nConfid
 ence: confirmed\nTicker NVO (confidence 0.95)\nSource: https://www.accessd
 ata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=76132
 6\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761326
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9d75cb50a0a110a87b07@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260319
DTEND;VALUE=DATE:20260320
SUMMARY:NVO APPROVAL: WEGOVY\; WEGOVY FLEXTOUCH\; WEGOVY HD
DESCRIPTION:Approved 2026-03-19: WEGOVY\; WEGOVY FLEXTOUCH\; WEGOVY HD (NDA
 215256 SUPPL29)\nConfidence: confirmed\nTicker NVO (confidence 0.95)\nSour
 ce: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvi
 ew.process&ApplNo=215256\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215256
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9310253c4bc30e809b28@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260227
DTEND;VALUE=DATE:20260228
SUMMARY:NVO APPROVAL: SOGROYA
DESCRIPTION:Approved 2026-02-27: SOGROYA (BLA761156 SUPPL15)\nConfidence: c
 onfirmed\nTicker NVO (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761156
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c2fb151cf8b7b3ec4ece@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260227
DTEND;VALUE=DATE:20260228
SUMMARY:NVO APPROVAL: SOGROYA
DESCRIPTION:Approved 2026-02-27: SOGROYA (BLA761156 SUPPL14)\nConfidence: c
 onfirmed\nTicker NVO (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761156
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:8bf0edeac21ab807c08e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260227
DTEND;VALUE=DATE:20260228
SUMMARY:NVO APPROVAL: SOGROYA
DESCRIPTION:Approved 2026-02-27: SOGROYA (BLA761156 SUPPL12)\nConfidence: c
 onfirmed\nTicker NVO (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761156
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:371d86d53371e24ab450@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251222
DTEND;VALUE=DATE:20251223
SUMMARY:NVO APPROVAL: WEGOVY
DESCRIPTION:Approved 2025-12-22: WEGOVY (NDA218316 ORIG1)\nConfidence: conf
 irmed\nTicker NVO (confidence 0.95)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218316
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6771e90fa8c37e1428bd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251121
DTEND;VALUE=DATE:20251122
SUMMARY:NVO APPROVAL: WEGOVY\; WEGOVY FLEXTOUCH\; WEGOVY HD
DESCRIPTION:Approved 2025-11-21: WEGOVY\; WEGOVY FLEXTOUCH\; WEGOVY HD (NDA
 215256 SUPPL23)\nConfidence: confirmed\nTicker NVO (confidence 0.95)\nSour
 ce: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvi
 ew.process&ApplNo=215256\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215256
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
